NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

Cingulate logo
$4.51 -0.75 (-14.26%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$4.55 +0.04 (+0.91%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cingulate Stock (NASDAQ:CING)

Advanced

Key Stats

Today's Range
$4.40
▼
$5.24
50-Day Range
$3.75
▼
$5.53
52-Week Range
$3.16
▼
$11.89
Volume
970,986 shs
Average Volume
151,732 shs
Market Capitalization
$67.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00
Consensus Rating
Moderate Buy

Company Overview

Cingulate is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD). The company’s approach is to improve how existing medicines are delivered over the course of the day.

Its lead candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate designed to provide multiple timed releases of medication. Cingulate is also developing CTx-1302, another candidate for ADHD.

The company uses its proprietary Precision Timed Release drug-delivery platform to develop these candidates. Cingulate is based in the United States and is focused on advancing its therapies through clinical development.

AI Generated. May Contain Errors.

Cingulate Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

CING MarketRank™: 
1.83589956998 of 5 stars

Cingulate scored higher than 37% of companies evaluated by MarketBeat, and ranked 657th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Cingulate has a consensus price target of $27.00, representing about 498.7% upside from its current price of $4.51.

  • Amount of Analyst Coverage

    Cingulate has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cingulate's stock forecast and price target.
  • Earnings Growth

    Earnings for Cingulate are expected to grow in the coming year, from ($2.19) to ($0.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cingulate is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cingulate is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cingulate has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.53% of the float of Cingulate has been sold short.
  • Short Interest Ratio / Days to Cover

    Cingulate has a short interest ratio ("days to cover") of 7.52.
  • Change versus previous month

    Short interest in Cingulate has recently increased by 2.03%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cingulate does not currently pay a dividend.

  • Dividend Growth

    Cingulate does not have a long track record of dividend growth.

  • News Sentiment

    Cingulate has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Cingulate this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cingulate insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.30% of the stock of Cingulate is held by insiders.

  • Percentage Held by Institutions

    41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cingulate's insider trading history.
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CING Stock News Headlines

Cingulate (NASDAQ:CING) Stock Dropped to "Strong Sell" by Wall Street Zen
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Headlines

CING Stock Analysis - Frequently Asked Questions

Cingulate's stock was trading at $4.34 at the beginning of 2026. Since then, CING shares have increased by 3.9% and is now trading at $4.51.

Cingulate Inc. (NASDAQ:CING) issued its earnings results on Friday, November, 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.10.

Cingulate's stock reverse split before market open on Thursday, November 30th 2023.The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cingulate (CING) raised $29 million in an initial public offering on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Oncobiologics (OTLK), Qualcomm (QCOM), SoundHound AI (SOUN), Crescent Energy (CRGY), International Business Machines (IBM) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

Last Earnings
11/13/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CING
CIK
1862150
Fax
N/A
Employees
14
Year Founded
2012

Price Target and Rating

High Price Target
$52.00
Low Price Target
$9.00
Potential Upside/Downside
+498.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.45 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-177.94%
Return on Assets
-108.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.90
Quick Ratio
3.50

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.39 per share
Price / Book
3.24

Miscellaneous

Outstanding Shares
14,960,000
Free Float
14,170,000
Market Cap
$67.47 million
Optionable
Optionable
Beta
-0.88

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:CING) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners